A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting

Phase 2

Eltrekibart & MirikizumabA Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Sponsor:

Eli Lilly and Company

Code:

NCT06598943

Conditions

Ulcerative Colitis

Ulcerative Colitis Chronic

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Eltrekibart

Mirikizumab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-08. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2025-11-06.